

## Eisai Co., Ltd. Financial Trend

### Financial Results & Managerial Indices

		FY 2001	FY 2002	FY 2003	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011 (forecast)	*Adjusted amounts
Net Sales	billion yen	431.7	466.6	500.2	533.0	601.3	674.1	734.3	781.7	803.2	768.9	654.0	654.0
R&D Expenses	billion yen	55.0	59.7	69.0	78.3	93.2	108.3	225.4	156.1	179.1	145.0	123.5	123.5
Operating Income	billion yen	72.7	75.9	83.1	86.8	95.7	105.3	17.7	91.8	86.4	113.1	100.0	100.0
Net Income (Loss)	billion yen	36.5	41.0	50.1	55.5	63.4	70.6	(17.0)	47.7	40.3	67.4	60.5	67.5
Sales by Overseas Subsidiaries/Net sales	%	42.9	46.3	47.8	49.7	52.6	56.7	57.4	57.5	55.2	49.6	-	-
Total Overseas Sales/Net sales	%	46.2	50.0	52.4	54.1	57.2	60.9	61.9	60.8	58.0	52.2	-	-
Free Cash Flows	billion yen	32.1	31.1	48.9	10.5	43.6	28.6	(415.9)	59.3	52.9	100.3	-	-
Cash Income	billion yen						97.6	106.9	119.0	126.4	120.0	109.0	116.0
Dividends On Equity (DOE)	%	2.4	2.5	2.6	3.7	5.3	6.4	7.4	9.1	10.1	10.4	10.7	10.7
Return On Equity (ROE)	%	10.3	10.9	12.4	12.6	13.0	13.2	(3.4)	10.9	9.6	16.4	15.1	16.7
Dividend Payout Ratio (DPR)	%	23.3	22.7	20.9	29.0	40.6	48.4	-	83.7	105.9	63.4	70.7	63.3
Dividends Per Share (DPS)	yen	29.0	32.0	36.0	56.0	90.0	120.0	130.0	140.0	150.0	150.0	150.0	150.0
Earnings (Loss) Per Share (EPS)	yen	123.5	141.2	172.1	193.4	221.9	247.8	(59.8)	167.3	141.6	236.5	212.3	236.9
Cash Income Per Share	yen						342.7	375.8	417.8	443.7	421.3	382.5	407.1

\* Free cash flows="Net cash provided by operating activities"- "Capital expenditures (including acquisition and others)"

\* DOE and ROE recorded in FY 2009 and before have been reclassified into the current classifications.


\* Cash Income: the total amount of cash available for investments for growth, business development, dividend payments, repayment of borrowings, and other expenditures. It reflects the Company's ability to generate cash.

(Calculation method: Net income (loss) + Depreciation of PP&E and amortization of intangible assets + In-process R&D expenses + Amortization of goodwill + Loss on impairment of long-lived assets (including loss on devaluation of investment securities))

\* In-process R&D expenses (87.4 billion yen) incurred in connection with the acquisition of MGI PHARMA, INC. were recorded in FY 2007.

\* In-process R&D expenses (23.9 billion yen) incurred in connection with the acquisition of AkaRx, Inc. were recorded in FY 2009.

\* Adjusted amounts shown in FY 2011(forecast) exclude the impact of the changes to the tax rate that accompanied the revisions to the Corporation Tax Act promulgated in December 2011.



The Company's performance or financial results could differ materially from these forward looking statements due to risks and uncertainties (i.e. economic and regulatory conditions, risks involved in research & development, marketing authorization) affecting the pharmaceutical industry.